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TO THE EDITOR
Chronic myeloid leukemia (CML) is a myeloproliferative disorder which originates in a multipotent hematopoietic stem cell. 95% of the CML patients have a Philadelphia (Ph) chromosome, which results from the translocation t(9;22)(q34;q11). In approximately 5 to 10% of the cases, there is a complex translocation with three to five chromosomes implicated with chromosomes 9 and 22. In some cases only, a masked Ph chromosome can be found with a 'normal' karyotype, as a result of a cryptic rearrangement.
The Ph chromosome translocation results in the formation of the 5′ bcr-3′ abl fusion gene, usually located on the Ph chromosome, which transcript induces the synthesis of a new protein having an enhanced tyrosin kinase activity compared to the wild-type ABL tyrosine kinase and leading to an abnormal signal of cellular proliferation.
With the new fluorescence in situ hybridization (FISH) methodologies, a previously unrecognized deletion of the 5′ abl region on the der(9) was found in CML. The aim of our study was to estimate the frequency of the deletion of the 5′ abl region among French CML patients and compare it with previously published reports.
Bone marrow samples from 112 patients with CML were investigated using banding techniques. 65 patients were investigated at diagnosis and during follow-up, while 47 patients, in whom the diagnosis was made prior to 1995, were only studied during follow-up. 103 of the 112 patients had a classical t(9;22)(q32;q11) translocation, one patient showed a normal karyotype and eight had a variant Ph chromosome translocation. Three-way Ph translocations were found in seven patients. Chromosome 4 was involved in two cases and chromosomes 3, 11, 14, 17, and 16 in one case each; in the latter patient, a ring of the derivative chromosome 9 was found. The eighth patient had a five-way Ph translocation, t(2;9;16;22;22).
Using LSI BCR/ABL dual ES color probe (AdGenix, Voisins le Bretonneux, France), the bcr-abl fusion gene was detected on the Ph chromosome in all 112 cases. In the patient with a normal karyotype in conventional cytogenetics, a masked Ph chromosome was identified. It involved the insertion of part of abl into bcr on an apparently normal chromosome 22, resulting in a bcr-abl fusion gene. The breakpoint was located in the major breakpoint cluster region (M-bcr) in 99% of the cases (111/112) and in the minor breakpoint cluster region (m-bcr) in 1% (1/112).
The deletion of the 5′ abl region was detected in nine patients. It was found at diagnosis in six patients and during follow-up in three more patients because there was no sample available at diagnosis for these latter patients. With D-FISH (Qbiogene), we confirmed the deletion of the 5′ abl region among all nine patients. In addition, we found a double deletion of the 5′ abl region and 3′ bcr region on der(9) among eight patients; a patient showed a deletion of 5′ abl solely. When the deletion was seen in a patient, it was present in all the Ph-positive metaphases and nuclei of all the samples studied at diagnosis and during follow-up. In these patients we never identified cells carrying the Ph translocation without the deletion. Our results suggest that the deletion of the derivative chromosome 9 appears at the same time as the formation of the translocation and does not constitute a clonal evolution, signing a progression of the disease.
Huntly et al 1 using triple FISH with ASS, ABL and BCR probes, analyzed samples of CML patients at diagnosis or/and during follow-up in chronic phase or/and at blastic crisis. They concluded that the deletion of the derivative chromosome 9 occurred at the time of the Leukemia translocation because the frequencies of deletion observed in different phases of the disease were similar. They also showed that the deletion of the 3′ bcr region was associated with 5′ abl region loss on the der(9) in 93.75% of the cases. Furthermore, in the paired samples (at diagnosis and during follow-up), no cell analyzed after disease progression had acquired a deletion without being present in the chronic phase. Moreover, they found that every cell with the deletion carried both the Ph chromosome translocation and the deletion. These results were corroborated by Kolomietz et al, 2 who demonstrated that sequences that flank breakpoint regions can be deleted during the formation of other translocations. They found a deletion of the 5′ abl region on der(9) associated with both Ph chromosome positive CML and acute lymphoblastic leukemia (ALL), but also a deletion of the 3′ region of the MLL gene associated with MLL translocations in patients with ALL and acute myeloblastic leukemia (AML).
Two patients with the deletion had a complex Ph chromosome translocation and seven a classical t(9;22) translocation. The difference in the frequencies of deletion observed between both groups of patients (25% and 6.9%, respectively) was borderline significant (P = 0.069).
The frequency of the deletion of the 5′ abl region has been assessed in the last 3 years by several workers both in classical and complex Ph translocations (Table 1) . Over 1000 patients have been studied; the mean value of the deletion rate was 15.7% (183/1166), with a range varying from 8.0 to 32.7%. We, as others, found that the prevalence of deletions was significantly higher in patients with variant Ph chromosome translocations (45/116) than in those with a classical (9;22) translocation (72/584) (mean values: 38.8% vs 12.3%, 2 = 48.69; P Ͻ 0.0001). This is consistent with a model in which the complex recombinant events that took place during the formation of the variant Ph chromosome translocations have a certain probability of deletions.
3
In conclusion, our results from France corroborate those previously published. The deletions observed in the region of the abl-bcr fusion gene on the derivative chromosome 9 do not differ from published data from the USA and other countries in Europe. 2 In humans a study on children with osteogenesis imperfecta receiving allogeneic MSC indicated the presence of donor cells on in vitro osteoblast culture albeit at a low level.
3 MSC have also immuno suppressive properties and can induce tolerance. 4 Although severe aplastic anemia (SAA) is an auto-immune disease where the stroma usually functions normally, damage of the microenvironment has been observed in a subset of SAA patients. 5 We report here a 68-year-old woman patient with end stage SAA refractory to administration of growth factors, cyclosporine A, antithymocyte globuline and ineligible for an allogeneic hematopoietic stem cell transplantation (HSCT). This patient received two infusions of allogeneic MSC, in order to improve a possible defective BM stroma, to stimulate hypothetical residual HSC by local production of hematopoietic growth factors, and to gain benefit from the immunosuppressive properties of MSC on the auto-immune mechanism of SAA.
Forty ml of BM was harvested from the posterior iliac crest of the son of the patient. BM mononuclear cells were seeded in long-term marrow culture for ex vivo MSC isolation and expansion. 6 A total of 10 × 10 6 MSC/kg of patient body weight was obtained. The MSC purity was assessed by flow cytometry: cells were SH2, SH3 positive and CD34, CD45 negative. The day before MSC infusion, the patient received a light conditioning regimen comprising cyclophosphamide 20 mg/kg in order to allow engraftment of allogeneic MSC. On the following day, 2 × 10 6 MSC/kg were infused intravenously. Three weeks later no recovery of hematopoieisis was observed; the clinical condition of the patient worsened mainly due to progression of a previous invasive fungal infection. A second infusion of 6 × 10 6 MSC/kg without any conditioning regimen was then performed. Thirty-four days after the second infusion, no effect on hematopoiesis was observed and the patient died from invasive fungal infection. BM analysis showed BM partial recovery of stroma and allogeneic MSC were detected in the recipient BM, suggesting engraftment.
Changes in BM stroma were documented by BM biopsies and colony-forming unit fibroblast (CFU-F) clonogenic assays for stromal cells. Before MSC infusion, the biopsy showed no residual hematopoietic tissue, interstitial hemorrhage, edema, adipocytic necrosis and no stromal cells as suggested by the absence of positive cell immunostaining with vimentine (Figure 1) . After MSC infusion, although there was no recovery of hematopoietic tissue, interstitial hemorrhage, edema and adipocytic necrosis all disappeared, stromal spindleshaped cells became visible with vimentin immunostaining (Figure 2) .
